Suraksha Diagno. Q1 FY27 Results (NSE: SURAKSHA)

· Analysis by Alpha Inflection

Signal: Growth decelerated

The read

The earnings inflected positively after FY26's margin contraction: standalone EBITDA margin expanded to 36.2% from the prior Q1FY26 trend of 32.7%, while EBITDA grew 22.3% versus revenue growth of 19.6% and PAT grew 27.7%; the improvement is operationally credible, but subsidiary losses and the Meghalaya dispute provision constrain consolidated quality.

Suraksha Diagno. Q1 FY27 key financials
MetricValueYoYQoQ
Revenue₹84.09 Cr19.6%N/A
EBIT₹19.88 Cr26.0%
Net profit₹12.58 Cr27.7%
EPS₹2.4228.0%
EBIT margin36.2%

P&L walk

The group includes six subsidiaries that reported ₹428.70 lakh of revenue and a ₹117.84 lakh net loss before consolidation adjustments; consolidated operating momentum therefore remains dependent on the standalone parent.

Segments

There is no reportable operating-segment split, but subsidiaries reported ₹428.70 lakh of revenue and a ₹117.84 lakh loss before consolidation; the group perimeter is therefore a drag relative to the standalone parent.

Key positives

Key concerns

View original filing

Research and educational content only. Not investment advice.